CD8A and neoplasm: discovered that by downregulating L-selectin expression on the surface of CD4+ and CD8+ T cells via plasma membrane production of ADAM17 (a disintegrin and metalloproteinase domain 17), MDSCs in BC restrict the activation and entrance of naive T cells into LNs and the transport to tumors, ultimately suppressing anti-tumor immunity (56).